Trials / Completed
CompletedNCT03948191
99Tc-MDP for Thyroid-Associated Ophthalmopathy
A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Dalian University · Academic / Other
- Sex
- All
- Age
- 18 Years – 76 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylprednisolone | 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks. |
| DRUG | 99Tc-MDP(99Technetium-Methylenediphosphonate Injection) | 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions. |
Timeline
- Start date
- 2017-10-16
- Primary completion
- 2018-12-30
- Completion
- 2019-03-31
- First posted
- 2019-05-13
- Last updated
- 2019-05-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03948191. Inclusion in this directory is not an endorsement.